trial · primary record
MK-1045
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2029-03-30 |
| Primary endpoint | Number of Participants who Experience a Dose-limiting Toxicity (DLT) |
| Registry ID | NCT06189391 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:12.864Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06189391
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Mk-1045 · compound